Small caps round-up: TEG, Deltex, Ultrasis
Loss-making green technology company TEG Group has entered into a further contract with recycling firm Viridor to process additional volumes of green and food waste in TEG's network of facilities. The contract will run until April 2014. The revenue over the term of the contract will depend upon the volume of waste delivered by Viridor over the period.
Loss-making green technology company TEG Group has entered into a further contract with recycling firm Viridor to process additional volumes of green and food waste in TEG's network of facilities. The contract will run until April 2014. The revenue over the term of the contract will depend upon the volume of waste delivered by Viridor over the period.
Deltex Medical, the oesophageal Doppler monitor maker, is to raise in the region of £1.5m through a placing of 6.1m new shares at 26p each. The company said it is expecting an increase in orders which will require an increase in working capital, hence the fund raising. The group added that UK surgical probe sales in the first quarter were up 40% year-on-year, a significant increase over both the compound annual growth rate of 20% since the launch of surgical probes in 2004 and the 16% increase in UK surgical probe sales achieved in 2011 compared to 2010. The UK surgical installed base increased by 38 monitors to 557 by March 31st 2012. Sales of probes in export markets in the first quarter were also ahead of 2011, driven by increased uptake in several of Deltex's larger export markets.
Interactive healthcare company Ultrasis has been hit hard by the spending slow-down in the National Health Service (NHS) and may need to take advantage of its own 'Beating the Blues' anxiety programme. Revenue in the six months to the end of January slumped to £0.51m from £1.44m at the interim stage the year before. The company slipped into the red, posting a loss before tax of £0.77m versus a profit the year before of £0.19m. Cash reserves are dwindling fast, and stood at £1.42m at the end of January 2012 versus £2.12m a year earlier. "The current structural reorganisation in the NHS has resulted in a pause in revenue but when the new structures, which are designed to focus on efficient deployment of resources, are fully operational we believe that the cost effective solution that 'Beating the Blues' offers will have direct economic relevance to our NHS customer," the company said.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
-
Who is the richest person in the world?
The top five richest people in the world have a combined net worth of $825 billion. Who takes the crown for the richest person in the world?
By Vaishali Varu Published
-
Top 10 stocks with highest growth over past decade - from Nvidia, Microsoft to Netflix, which companies made you the most money?
We reveal the 10 global companies with the biggest returns since 2013. One firm has posted an astonishing 9,870% return, meaning a £1,000 investment would now be worth almost £82,000.
By Ruth Emery Published